



Session	Start-ups/SMEs looking for Finance: pre-seed/angel/seed funding
Title	From Infant Formula to the Future of Human Nutrition
Company	Hulk Bio
Speaker	Christina Rode, PhD
Keywords feedstock (max. 2)	Human cells
Keywords technology (max 2)	Cell culture
Keywords End-Product (max 2)	Milk Bioactives
Abstract:	
Hulk Bio is pioneering the next frontier in infant nutrition by producing bioactive components of human milk directly from human cells. Despite decades of use, infant formula cannot replicate the immune protection, microbiome development, or cognitive benefits of breast milk. Formula-fed infants face higher risks of infection, allergy, and long-term metabolic disease. Our breakthrough cell-based platform bridges that gap, unlocking access to true human milk bioactives at scale for the first time. Our unique advantage lies in producing bioidentical, scalable, and diverse human milk bioactives for multi-vertical applications in nutrition, gut health, and wellness. Unlike donor-dependent or fermentation-based approaches, our platform delivers the full spectrum of bioactives found in natural milk, ensuring consistent quality, reliable supply, and functional diversity. Our B2B model centres on ingredient supply, enabling infant formula, nutraceutical and wellness companies to transform their products with authentic human milk bioactives. This foundation also creates opportunities for licensing partnerships as well as the expansion into specialised product lines, positioning Hulk Bio as the enabling platform behind next-gen nutrition and wellness. Led by deep scientific experts and supported by experienced commercial advisors, Hulk Bio will redefine infant feeding, improve global health outcomes, and capture shares of the \$53B infant formula market and the \$200B+ bioactives market underserved by current technologies. Our pre-seed round will accelerate development, scale, and secure our IP.	